{"protocolSection":{"identificationModule":{"nctId":"NCT00730691","orgStudyIdInfo":{"id":"LuAA21004_308"},"secondaryIdInfos":[{"id":"U1111-1114-3966","type":"REGISTRY","domain":"WHO"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder"},"statusModule":{"statusVerifiedDate":"2013-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-06"},"primaryCompletionDateStruct":{"date":"2009-02","type":"ACTUAL"},"completionDateStruct":{"date":"2009-02","type":"ACTUAL"},"studyFirstSubmitDate":"2008-08-06","studyFirstSubmitQcDate":"2008-08-06","studyFirstPostDateStruct":{"date":"2008-08-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-10-25","resultsFirstSubmitQcDate":"2013-10-25","resultsFirstPostDateStruct":{"date":"2013-12-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-10-25","lastUpdatePostDateStruct":{"date":"2013-12-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Takeda","class":"INDUSTRY"},"collaborators":[{"name":"H. Lundbeck A/S","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.","detailedDescription":"Participants in this study will be randomly assigned to receive either 2.5 mg, 5 mg or 10 mg of vortioxetine, once daily, 60 mg of duloxetine once daily, or a placebo once daily for eight weeks.\n\nParticipants will be seen weekly during the first 2 weeks of treatment, and then every 2 weeks up to the end of the 8-week treatment period. Participants who complete the 8-week treatment period will enter a 2-week discontinuation period in order to assess potential discontinuation symptoms. Total commitment time is up to 12 weeks."},"conditionsModule":{"conditions":["Generalized Anxiety Disorder"],"keywords":["Generalized Anxiety Disorder","Mood Disorder","Affective Disorder","Anxiety Disorder","Drug Therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":781,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks.","interventionNames":["Drug: Placebo"]},{"label":"Vortioxetine 2.5 mg","type":"EXPERIMENTAL","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.","interventionNames":["Drug: Placebo","Drug: Vortioxetine"]},{"label":"Vortioxetine 5 mg","type":"EXPERIMENTAL","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.","interventionNames":["Drug: Placebo","Drug: Vortioxetine"]},{"label":"Vortioxetine 10 mg","type":"EXPERIMENTAL","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.","interventionNames":["Drug: Placebo","Drug: Vortioxetine"]},{"label":"Duloxetine 60 mg","type":"ACTIVE_COMPARATOR","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.","interventionNames":["Drug: Duloxetine"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Placebo-matching capsules","armGroupLabels":["Placebo","Vortioxetine 10 mg","Vortioxetine 2.5 mg","Vortioxetine 5 mg"]},{"type":"DRUG","name":"Vortioxetine","description":"Encapsulated vortioxetine immediate release tablets","armGroupLabels":["Vortioxetine 10 mg","Vortioxetine 2.5 mg","Vortioxetine 5 mg"],"otherNames":["Lu AA21004","Brintellix®"]},{"type":"DRUG","name":"Duloxetine","description":"Overencapsulated duloxetine capsules","armGroupLabels":["Duloxetine 60 mg"],"otherNames":["Cymbalta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Week 8"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8","description":"The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Week 8"},{"measure":"Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8","description":"The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Week 8"},{"measure":"Change From Baseline in Sheehan Disability Scale (SDS) at Week 8","description":"The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Week 8"},{"measure":"Percentage of Responders in HAM-A Total Score at Week 8","description":"Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","timeFrame":"Week 8"},{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Week 8"},{"measure":"Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1, 2, 4 and 6"},{"measure":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed","description":"The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1 and 4"},{"measure":"Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed","description":"The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1, 2, 4 and 6"},{"measure":"Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed","description":"The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1, 2 and 4"},{"measure":"Percentage of Responders in HAM-A Total Score at Other Weeks Assessed","description":"Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","timeFrame":"Baseline and Weeks 1, 2, 4 and 6"},{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to weeks 1, 2, 4 and 6"},{"measure":"Percentage of Participants in HAM-A Remission at Each Week Assessed","description":"Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","timeFrame":"Weeks 1, 2, 4, 6 and 8"},{"measure":"Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)","description":"The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1, 2, 4, 6 and 8"},{"measure":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed","description":"The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.","timeFrame":"Baseline to Weeks 1, 4 and 8"},{"measure":"Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire","description":"Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.","timeFrame":"Baseline and Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a primary diagnosis of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR®) criteria (classification code 300.02).\n* Has a Hamilton Anxiety Scale total score ≥ 20. Has a Hamilton Anxiety Scale score ≥2 on both item 1 (anxious mood) and item 2 (tension).\n* Has a Montgomery-Åsberg Depression Rating Scale total score ≤16.\n\nExclusion Criteria:\n\n* Had received any investigational compound \\<30 days before Screening or 5 half-lives prior to Screening, whichever is longer.\n* Received Lu AA21004 in a previous clinical study.\n* Was a study site employee, or an immediate family member (ie, spouse, parent, child, or sibling) of a study site employee involved in conduct of this study.\n* Has 1 or more of the following:\n\n  * Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the DSM-IV-TR® (as assessed by the Mini International Neuropsychiatric Interview \\[MINI\\]).\n  * Current or past history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.\n  * Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR® and must have a negative urine drug screen prior to Baseline.\n  * Presence or history of a clinically significant neurological disorder (including epilepsy).\n  * Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).\n  * Any Axis II disorder that might compromise the study.\n* Has known sensitivity to duloxetine.\n* Is taking excluded medications\n* Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.\n* Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitor and/or serotonin-norepinephrine reuptake inhibitors.\n* Has received electroconvulsive therapy within 6 months prior to Screening.\n* Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.\n* Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.\n* Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.\n* Has an alanine aminotransferase, aspartate aminotransferase, or total bilirubin level \\>1.5 times the upper limit of normal.\n* Has a serum creatinine level \\>1.5 upper limit of normal.\n* Has a previous history of cancer that had been in remission for less than 5 years.\n* Hasclinically significant abnormal vital signs as determined by the investigator.\n* Has a history of lack of response to previous adequate treatment with duloxetine for any Generalized Anxiety Disorder episode.\n* Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at the Screening Visit\n* Has a thyroid stimulating hormone value outside the normal range.\n* Has an abnormal electrocardiogram.\n* has a disease or was taking medications that, in the opinion of the investigator, could have interfered with the assessments of safety, tolerability, or efficacy.\n* The patient, in the opinion of the investigator, was unlikely to comply with the clinical study protocol or was unsuitable for any reason.\n* Had previously been enrolled in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director Clinical Science","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Anaheim","state":"California","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"city":"Beverly Hills","state":"California","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"city":"Fresno","state":"California","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"city":"Los Angeles","state":"California","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"city":"Oceanside","state":"California","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"city":"San Diego","state":"California","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"city":"Sherman Oaks","state":"California","country":"United States","geoPoint":{"lat":34.15112,"lon":-118.44925}},{"city":"Widomar","state":"California","country":"United States"},{"city":"Denver","state":"Colorado","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"city":"Farmington","state":"Connecticut","country":"United States","geoPoint":{"lat":41.71982,"lon":-72.83204}},{"city":"Norwalk","state":"Connecticut","country":"United States","geoPoint":{"lat":41.1176,"lon":-73.4079}},{"city":"Coral Gables","state":"Florida","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"city":"Jacksonville","state":"Florida","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"city":"Maitland","state":"Florida","country":"United States","geoPoint":{"lat":28.62778,"lon":-81.36312}},{"city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"city":"Orlando","state":"Florida","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"city":"Tampa","state":"Florida","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"city":"West Palm Beach","state":"Florida","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"city":"Winter Park","state":"Florida","country":"United States","geoPoint":{"lat":28.6,"lon":-81.33924}},{"city":"Atlanta","state":"Georgia","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"city":"Roswell","state":"Georgia","country":"United States","geoPoint":{"lat":34.02316,"lon":-84.36159}},{"city":"Smyrna","state":"Georgia","country":"United States","geoPoint":{"lat":33.88399,"lon":-84.51438}},{"city":"Honolulu","state":"Hawaii","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"city":"Oakbrook Ter","state":"Illinois","country":"United States"},{"city":"Terre Haute","state":"Indiana","country":"United States","geoPoint":{"lat":39.4667,"lon":-87.41391}},{"city":"Owensboro","state":"Kentucky","country":"United States","geoPoint":{"lat":37.77422,"lon":-87.11333}},{"city":"Shreveport","state":"Louisiana","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"city":"Rockville","state":"Maryland","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"city":"Chesterfield","state":"Missouri","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"city":"Nashua","state":"New Hampshire","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"city":"Clementon","state":"New Jersey","country":"United States","geoPoint":{"lat":39.8115,"lon":-74.98294}},{"city":"Princeton","state":"New Jersey","country":"United States","geoPoint":{"lat":40.34872,"lon":-74.65905}},{"city":"Albuquerque","state":"New Mexico","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"city":"Brooklyn","state":"New York","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"city":"Cedarhurst","state":"New York","country":"United States","geoPoint":{"lat":40.62288,"lon":-73.7243}},{"city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"Rochester","state":"New York","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"city":"Staten Island","state":"New York","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"city":"Charlotte","state":"North Carolina","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"city":"Raleigh","state":"North Carolina","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"city":"Beachwood","state":"Ohio","country":"United States","geoPoint":{"lat":41.4645,"lon":-81.50873}},{"city":"Cleveland","state":"Ohio","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"city":"Dayton","state":"Ohio","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"city":"Toledo","state":"Ohio","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"city":"Eugene","state":"Oregon","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"city":"Salem","state":"Oregon","country":"United States","geoPoint":{"lat":44.9429,"lon":-123.0351}},{"city":"Allentown","state":"Pennsylvania","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"city":"Media","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.91678,"lon":-75.38769}},{"city":"Philadelphia","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"city":"Columbia","state":"South Carolina","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"city":"Memphis","state":"Tennessee","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"city":"Nashville","state":"Tennessee","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"city":"DeSoto","state":"Texas","country":"United States","geoPoint":{"lat":32.58986,"lon":-96.85695}},{"city":"Houston","state":"Texas","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"city":"Lake Jackson","state":"Texas","country":"United States","geoPoint":{"lat":29.03386,"lon":-95.43439}},{"city":"Wichita Falls","state":"Texas","country":"United States","geoPoint":{"lat":33.91371,"lon":-98.49339}},{"city":"Midvale","state":"Utah","country":"United States","geoPoint":{"lat":40.61106,"lon":-111.89994}},{"city":"Woodstock","state":"Vermont","country":"United States","geoPoint":{"lat":43.62424,"lon":-72.51843}},{"city":"Richmond","state":"Virginia","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"city":"Seattle","state":"Washington","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"city":"Brown Deer","state":"Wisconsin","country":"United States","geoPoint":{"lat":43.16334,"lon":-87.96453}},{"city":"Middleton","state":"Wisconsin","country":"United States","geoPoint":{"lat":43.09722,"lon":-89.50429}},{"city":"Milwaukee","state":"Wisconsin","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}}]},"referencesModule":{"references":[{"pmid":"24341301","type":"DERIVED","citation":"Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014 Jan;68(1):49-59. doi: 10.1111/ijcp.12328."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants with a diagnosis of generalized anxiety disorder were enrolled equally in 1 of 5 treatment groups, once a day placebo, 2.5 mg, 5 mg or 10 mg vortioxetine, or 60 mg duloxetine.","recruitmentDetails":"Participants took part in the study at 71 investigative sites in the United States from 20 June 2008 to 27 February 2009.","groups":[{"id":"FG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"FG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"FG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"FG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"FG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"156"},{"groupId":"FG002","comment":"One participant was randomized by error. Reason not completed is reported as Other.","numSubjects":"156"},{"groupId":"FG003","numSubjects":"156"},{"groupId":"FG004","numSubjects":"156"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"120"},{"groupId":"FG002","numSubjects":"117"},{"groupId":"FG003","numSubjects":"111"},{"groupId":"FG004","numSubjects":"106"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"36"},{"groupId":"FG002","numSubjects":"39"},{"groupId":"FG003","numSubjects":"45"},{"groupId":"FG004","numSubjects":"50"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"23"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Non-compliance with Study Drug","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"Protocol Deviations","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"5"}]},{"type":"Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"15"},{"groupId":"FG004","numSubjects":"13"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"BG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"BG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"BG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"BG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"156"},{"groupId":"BG003","value":"156"},{"groupId":"BG004","value":"156"},{"groupId":"BG005","value":"781"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.8","spread":"12.12"},{"groupId":"BG001","value":"39.2","spread":"11.90"},{"groupId":"BG002","value":"37.7","spread":"11.96"},{"groupId":"BG003","value":"39.8","spread":"12.33"},{"groupId":"BG004","value":"39.5","spread":"12.28"},{"groupId":"BG005","value":"38.6","spread":"12.14"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"≤55 years","categories":[{"measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"137"},{"groupId":"BG004","value":"137"},{"groupId":"BG005","value":"704"}]}]},{"title":">55 years","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"77"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"105"},{"groupId":"BG004","value":"113"},{"groupId":"BG005","value":"529"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"51"},{"groupId":"BG004","value":"43"},{"groupId":"BG005","value":"252"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race data only available for 154 participants in the vortioxetine 2.5 mg arm.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian (White, including Hispanic)","categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"124"},{"groupId":"BG003","value":"120"},{"groupId":"BG004","value":"121"},{"groupId":"BG005","value":"604"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"156"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"14"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}]},{"title":"Native Hawaiian/ Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"156"},{"groupId":"BG003","value":"156"},{"groupId":"BG004","value":"156"},{"groupId":"BG005","value":"781"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"84.40","spread":"25.426"},{"groupId":"BG001","value":"79.47","spread":"19.893"},{"groupId":"BG002","value":"80.98","spread":"20.312"},{"groupId":"BG003","value":"80.17","spread":"21.420"},{"groupId":"BG004","value":"79.51","spread":"20.090"},{"groupId":"BG005","value":"80.91","spread":"21.558"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"cm","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"168.74","spread":"9.605"},{"groupId":"BG001","value":"167.87","spread":"9.139"},{"groupId":"BG002","value":"169.25","spread":"9.282"},{"groupId":"BG003","value":"167.61","spread":"8.378"},{"groupId":"BG004","value":"167.94","spread":"9.300"},{"groupId":"BG005","value":"168.28","spread":"9.147"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.54","spread":"8.478"},{"groupId":"BG001","value":"28.19","spread":"6.651"},{"groupId":"BG002","value":"28.24","spread":"6.589"},{"groupId":"BG003","value":"28.49","spread":"7.058"},{"groupId":"BG004","value":"28.10","spread":"6.325"},{"groupId":"BG005","value":"28.51","spread":"7.064"}]}]}]},{"title":"Smoking Classification","description":"Smoking classification data available for 156 participants in the placebo arm.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never Smoked","categories":[{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"81"},{"groupId":"BG003","value":"85"},{"groupId":"BG004","value":"82"},{"groupId":"BG005","value":"425"}]}]},{"title":"Current Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"43"},{"groupId":"BG005","value":"214"}]}]},{"title":"Ex-smoker","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"141"}]}]}]},{"title":"Alcohol Consumption","description":"Alcohol consumption data available for 156 participants in the placebo arm.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never","categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"226"}]}]},{"title":"Once monthly or less often","categories":[{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"66"},{"groupId":"BG003","value":"49"},{"groupId":"BG004","value":"64"},{"groupId":"BG005","value":"300"}]}]},{"title":"Once a week","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"131"}]}]},{"title":"2 to 6 times per week","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"108"}]}]},{"title":"Daily","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"15"}]}]}]},{"title":"Hamilton Anxiety Scale Total Score","description":"Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (absent) to 56 (maximum severity).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24.4","spread":"3.73"},{"groupId":"BG001","value":"25.3","spread":"4.25"},{"groupId":"BG002","value":"25.0","spread":"3.57"},{"groupId":"BG003","value":"25.3","spread":"3.96"},{"groupId":"BG004","value":"25.0","spread":"3.94"},{"groupId":"BG005","value":"25.0","spread":"3.90"}]}]}]},{"title":"Clinical Global Impression - Severity scale score","description":"The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.3","spread":"0.56"},{"groupId":"BG001","value":"4.4","spread":"0.63"},{"groupId":"BG002","value":"4.4","spread":"0.59"},{"groupId":"BG003","value":"4.4","spread":"0.59"},{"groupId":"BG004","value":"4.4","spread":"0.62"},{"groupId":"BG005","value":"4.4","spread":"0.60"}]}]}]},{"title":"Hospital Anxiety and Depression - Anxiety subscale","description":"Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13.9","spread":"3.23"},{"groupId":"BG001","value":"13.8","spread":"3.40"},{"groupId":"BG002","value":"13.8","spread":"3.70"},{"groupId":"BG003","value":"14.0","spread":"3.02"},{"groupId":"BG004","value":"13.4","spread":"3.70"},{"groupId":"BG005","value":"13.8","spread":"3.41"}]}]}]},{"title":"Hospital Anxiety and Depression - Depression subscale","description":"Hospital Anxiety and Depression (HAD) Depression sub-scale consists of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). The depression subscale focuses on the state of lost interest and diminished pleasure response. Scores are summed and range from 0 to 21 (maximal severity).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.2","spread":"4.12"},{"groupId":"BG001","value":"8.2","spread":"3.83"},{"groupId":"BG002","value":"8.2","spread":"3.94"},{"groupId":"BG003","value":"8.5","spread":"3.59"},{"groupId":"BG004","value":"8.2","spread":"4.00"},{"groupId":"BG005","value":"8.2","spread":"3.89"}]}]}]},{"title":"Montgomery Åsberg Depression Rating Scale (MADRS) total score","description":"The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11.83","spread":"2.787"},{"groupId":"BG001","value":"12.24","spread":"3.279"},{"groupId":"BG002","value":"12.24","spread":"2.895"},{"groupId":"BG003","value":"12.47","spread":"2.868"},{"groupId":"BG004","value":"11.99","spread":"3.087"},{"groupId":"BG005","value":"12.16","spread":"2.989"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"The full analysis set (FAS) included all randomized patients who received at least 1 dose of study drug, and had at least 1 postbaseline value for assessment of primary efficacy. A mixed model for repeated measurements (MMRM) based on observed cases was used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"114"},{"groupId":"OG003","value":"111"},{"groupId":"OG004","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.27","spread":"0.595"},{"groupId":"OG001","value":"-12.23","spread":"0.600"},{"groupId":"OG002","value":"-11.57","spread":"0.606"},{"groupId":"OG003","value":"-11.66","spread":"0.606"},{"groupId":"OG004","value":"-13.87","spread":"0.635"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"P-values were tested at the 5% level of significance (ie, statistical significance if P\\<0.05) comparing each of the 3 doses of vortioxetine to placebo.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.255","pValueComment":"This treatment arm is not in the pre-specified testing sequence, a nominal p-value is provided.","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.62","ciUpperLimit":"0.69","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.843"},{"groupIds":["OG000","OG002"],"groupDescription":"To control for multiplicity, a pre-specified sequential testing procedure was applied to compare 10 mg and 5 mg vortioxetine to placebo; as soon as an endpoint was non-significant at 0.025, the testing procedure stopped for all subsequent endpoints.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.719","pValueComment":"Pre-specified sequential statistical testing procedure indicates that when p-value \\>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.96","ciUpperLimit":"1.35","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.843"},{"groupIds":["OG000","OG003"],"groupDescription":"To control for multiplicity, a pre-specified sequential testing procedure was applied to compare 10 mg and 5 mg vortioxetine to placebo; as soon as an endpoint was non-significant at 0.025, the testing procedure stopped for all subsequent endpoints.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.642","pValueComment":"Pre-specified sequential statistical testing procedure indicates that when p-value \\>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.06","ciUpperLimit":"1.27","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.848"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-2.60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.30","ciUpperLimit":"-0.89","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.869"}]},{"type":"SECONDARY","title":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8","description":"The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"111"},{"groupId":"OG004","value":"108"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.00","spread":"0.361"},{"groupId":"OG001","value":"-3.89","spread":"0.364"},{"groupId":"OG002","value":"-4.24","spread":"0.366"},{"groupId":"OG003","value":"-5.09","spread":"0.372"},{"groupId":"OG004","value":"-5.54","spread":"0.385"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.830","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"0.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.89","ciUpperLimit":"1.11","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.511"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.643","pValueComment":"Hierarchical testing stopped at the primary endpoint in the testing sequence, a nominal p-value is provided.","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.24","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.24","ciUpperLimit":"0.77","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.510"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.036","pValueComment":"Hierarchical testing stopped at the primary endpoint in the testing sequence, a nominal p-value is provided.","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.10","ciUpperLimit":"-0.07","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.517"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS mean Difference","paramValue":"-1.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.58","ciUpperLimit":"-0.50","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.527"}]},{"type":"SECONDARY","title":"Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8","description":"The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"114"},{"groupId":"OG003","value":"111"},{"groupId":"OG004","value":"106"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"0.091"},{"groupId":"OG001","value":"2.36","spread":"0.092"},{"groupId":"OG002","value":"2.38","spread":"0.093"},{"groupId":"OG003","value":"2.38","spread":"0.093"},{"groupId":"OG004","value":"2.03","spread":"0.098"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.407","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.36","ciUpperLimit":"0.15","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.129"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.533","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.33","ciUpperLimit":"0.17","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.129"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.491","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.34","ciUpperLimit":"0.17","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.130"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.70","ciUpperLimit":"-0.17","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.133"}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) at Week 8","description":"The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"95"},{"groupId":"OG003","value":"94"},{"groupId":"OG004","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.35","spread":"0.631"},{"groupId":"OG001","value":"-6.15","spread":"0.647"},{"groupId":"OG002","value":"-6.68","spread":"0.642"},{"groupId":"OG003","value":"-7.95","spread":"0.623"},{"groupId":"OG004","value":"-8.81","spread":"0.675"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.652","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"0.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.16","ciUpperLimit":"1.85","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.765"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.511","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.98","ciUpperLimit":"0.98","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.754"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.204","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.38","ciUpperLimit":"0.51","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.736"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-2.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.10","ciUpperLimit":"-1.03","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.781"}]},{"type":"SECONDARY","title":"Percentage of Responders in HAM-A Total Score at Week 8","description":"Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","populationDescription":"Full analysis set; Last observation carried forward (LOCF) was used.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2"},{"groupId":"OG001","value":"44.8"},{"groupId":"OG002","value":"42.6"},{"groupId":"OG003","value":"44.8"},{"groupId":"OG004","value":"51.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.641","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression with explanatory variables for treatment and Baseline HAM-A score.","paramType":"Odds Ratio (OR)","paramValue":"1.114","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.709","ciUpperLimit":"1.750"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.945","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression with explanatory variables for treatment and Baseline HAM-A score.","paramType":"Odds Ratio (OR)","paramValue":"1.016","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.643","ciUpperLimit":"1.605"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.641","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression with explanatory variables for treatment and Baseline HAM-A score.","paramType":"Odds Ratio (OR)","paramValue":"1.114","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.709","ciUpperLimit":"1.749"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.124","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression with explanatory variables for treatment and Baseline HAM-A score.","paramType":"Odds Ratio (OR)","paramValue":"1.427","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.907","ciUpperLimit":"2.246"}]},{"type":"SECONDARY","title":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set patients with a HAM-A Baseline score ≥25. A mixed model for repeated measurements (MMRM) based on observed cases was used.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.61","spread":"1.008"},{"groupId":"OG001","value":"-14.12","spread":"0.945"},{"groupId":"OG002","value":"-13.87","spread":"0.955"},{"groupId":"OG003","value":"-13.22","spread":"0.999"},{"groupId":"OG004","value":"-16.15","spread":"1.039"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.064","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-2.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.15","ciUpperLimit":"0.14","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.346"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.096","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-2.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.92","ciUpperLimit":"0.40","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.353"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.250","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-1.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.36","ciUpperLimit":"1.14","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.397"},{"groupIds":["OG000","OG004"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Mixed model for repeated measurements","statisticalComment":"P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.","paramType":"LS Mean Difference","paramValue":"-4.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.34","ciUpperLimit":"-1.73","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.425"}]},{"type":"SECONDARY","title":"Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1, 2, 4 and 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"149"}]}],"classes":[{"title":"Week 1 (n= 151, 149, 142, 149, 143)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.70","spread":"0.423"},{"groupId":"OG001","value":"-4.56","spread":"0.421"},{"groupId":"OG002","value":"-4.90","spread":"0.430"},{"groupId":"OG003","value":"-5.04","spread":"0.419"},{"groupId":"OG004","value":"-5.48","spread":"0.435"}]}]},{"title":"Week 2 (n=147, 145, 143, 147, 130)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.30","spread":"0.472"},{"groupId":"OG001","value":"-7.28","spread":"0.471"},{"groupId":"OG002","value":"-8.22","spread":"0.476"},{"groupId":"OG003","value":"-7.63","spread":"0.468"},{"groupId":"OG004","value":"-9.29","spread":"0.494"}]}]},{"title":"Week 4 (n= 139, 135, 132, 133, 116)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.66","spread":"0.518"},{"groupId":"OG001","value":"-9.77","spread":"0.520"},{"groupId":"OG002","value":"-9.84","spread":"0.525"},{"groupId":"OG003","value":"-9.73","spread":"0.519"},{"groupId":"OG004","value":"-11.13","spread":"0.553"}]}]},{"title":"Week 6 (n= 127, 123, 122, 120, 112)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.28","spread":"0.547"},{"groupId":"OG001","value":"-10.82","spread":"0.553"},{"groupId":"OG002","value":"-11.26","spread":"0.556"},{"groupId":"OG003","value":"-11.05","spread":"0.552"},{"groupId":"OG004","value":"-12.66","spread":"0.583"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed","description":"The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1 and 4","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"148"}]}],"classes":[{"title":"Week 1 (n=150, 149, 141, 149, 141)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"0.273"},{"groupId":"OG001","value":"-1.85","spread":"0.274"},{"groupId":"OG002","value":"-1.89","spread":"0.280"},{"groupId":"OG003","value":"-2.22","spread":"0.272"},{"groupId":"OG004","value":"-2.91","spread":"0.285"}]}]},{"title":"Week 4 (n=141, 142, 139, 141, 126)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.24","spread":"0.310"},{"groupId":"OG001","value":"-3.34","spread":"0.310"},{"groupId":"OG002","value":"-3.60","spread":"0.313"},{"groupId":"OG003","value":"-4.01","spread":"0.310"},{"groupId":"OG004","value":"-5.11","spread":"0.328"}]}]}]},{"type":"SECONDARY","title":"Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed","description":"The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1, 2, 4 and 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"147"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"148"}]}],"classes":[{"title":"Week 1 (n=151, 148, 141, 149, 141)","categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":"0.067"},{"groupId":"OG001","value":"3.46","spread":"0.068"},{"groupId":"OG002","value":"3.41","spread":"0.069"},{"groupId":"OG003","value":"3.40","spread":"0.067"},{"groupId":"OG004","value":"3.36","spread":"0.070"}]}]},{"title":"Week 2 (n=147, 145, 142, 147, 129)","categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"0.072"},{"groupId":"OG001","value":"3.08","spread":"0.072"},{"groupId":"OG002","value":"2.90","spread":"0.073"},{"groupId":"OG003","value":"2.96","spread":"0.072"},{"groupId":"OG004","value":"2.76","spread":"0.077"}]}]},{"title":"Week 4 (n=140, 135, 132, 134, 116)","categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"0.079"},{"groupId":"OG001","value":"2.67","spread":"0.080"},{"groupId":"OG002","value":"2.67","spread":"0.081"},{"groupId":"OG003","value":"2.68","spread":"0.080"},{"groupId":"OG004","value":"2.44","spread":"0.085"}]}]},{"title":"Week 6 (n=127, 123, 121, 120, 112)","categories":[{"measurements":[{"groupId":"OG000","value":"2.61","spread":"0.082"},{"groupId":"OG001","value":"2.53","spread":"0.083"},{"groupId":"OG002","value":"2.43","spread":"0.084"},{"groupId":"OG003","value":"2.41","spread":"0.083"},{"groupId":"OG004","value":"2.25","spread":"0.088"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed","description":"The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1, 2 and 4","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"118"},{"groupId":"OG003","value":"133"},{"groupId":"OG004","value":"119"}]}],"classes":[{"title":"Week 1 (n=116, 111, 109, 125, 112)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","spread":"0.506"},{"groupId":"OG001","value":"-2.74","spread":"0.521"},{"groupId":"OG002","value":"-3.28","spread":"0.521"},{"groupId":"OG003","value":"-4.11","spread":"0.483"},{"groupId":"OG004","value":"-4.74","spread":"0.521"}]}]},{"title":"Week 2 (n=116, 114, 116, 123, 103)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.53","spread":"0.536"},{"groupId":"OG001","value":"-4.18","spread":"0.547"},{"groupId":"OG002","value":"-5.02","spread":"0.542"},{"groupId":"OG003","value":"-5.46","spread":"0.514"},{"groupId":"OG004","value":"-7.09","spread":"0.563"}]}]},{"title":"Week 4 (n=108, 106, 106, 115, 91)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"0.590"},{"groupId":"OG001","value":"-4.98","spread":"0.604"},{"groupId":"OG002","value":"-5.92","spread":"0.600"},{"groupId":"OG003","value":"-6.47","spread":"0.568"},{"groupId":"OG004","value":"-7.95","spread":"0.632"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders in HAM-A Total Score at Other Weeks Assessed","description":"Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","populationDescription":"Full analysis set; LOCF was used. \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline and Weeks 1, 2, 4 and 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"149"}]}],"classes":[{"title":"Week 1 (n=151, 149, 142, 149, 143)","categories":[{"measurements":[{"groupId":"OG000","value":"11.3"},{"groupId":"OG001","value":"6.7"},{"groupId":"OG002","value":"8.5"},{"groupId":"OG003","value":"10.1"},{"groupId":"OG004","value":"16.8"}]}]},{"title":"Week 2 (n=154, 154, 147, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"20.8"},{"groupId":"OG001","value":"20.1"},{"groupId":"OG002","value":"21.1"},{"groupId":"OG003","value":"21.4"},{"groupId":"OG004","value":"28.9"}]}]},{"title":"Week 4 (n=154, 154, 148, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"26.0"},{"groupId":"OG001","value":"30.5"},{"groupId":"OG002","value":"32.4"},{"groupId":"OG003","value":"35.1"},{"groupId":"OG004","value":"42.3"}]}]},{"title":"Week 6 (n=154, 154, 148, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"36.4"},{"groupId":"OG001","value":"37.7"},{"groupId":"OG002","value":"40.5"},{"groupId":"OG003","value":"40.9"},{"groupId":"OG004","value":"47.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25","description":"The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set patients with a HAM-A Baseline score ≥25. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to weeks 1, 2, 4 and 6","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"74"},{"groupId":"OG003","value":"73"},{"groupId":"OG004","value":"70"}]}],"classes":[{"title":"Week 1 (n=63, 76, 70, 70, 66)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.32","spread":"0.787"},{"groupId":"OG001","value":"-6.07","spread":"0.719"},{"groupId":"OG002","value":"-5.96","spread":"0.749"},{"groupId":"OG003","value":"-5.94","spread":"0.740"},{"groupId":"OG004","value":"-6.78","spread":"0.770"}]}]},{"title":"Week 2 (n=62, 73, 70, 68, 62)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.55","spread":"0.856"},{"groupId":"OG001","value":"-8.82","spread":"0.785"},{"groupId":"OG002","value":"-10.18","spread":"0.810"},{"groupId":"OG003","value":"-8.51","spread":"0.808"},{"groupId":"OG004","value":"-10.40","spread":"0.844"}]}]},{"title":"Week 4 (n=60, 68, 67, 63, 54)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.61","spread":"0.901"},{"groupId":"OG001","value":"-11.61","spread":"0.837"},{"groupId":"OG002","value":"-12.87","spread":"0.854"},{"groupId":"OG003","value":"-10.98","spread":"0.862"},{"groupId":"OG004","value":"-12.56","spread":"0.914"}]}]},{"title":"Week 6 (n=58, 63, 62, 54, 51)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.72","spread":"0.937"},{"groupId":"OG001","value":"-12.86","spread":"0.880"},{"groupId":"OG002","value":"-14.11","spread":"0.895"},{"groupId":"OG003","value":"-12.75","spread":"0.918"},{"groupId":"OG004","value":"-14.35","spread":"0.961"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in HAM-A Remission at Each Week Assessed","description":"Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).","populationDescription":"Full analysis set. LOCF was used. \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Weeks 1, 2, 4, 6 and 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"149"}]}],"classes":[{"title":"Week 1 (n=151, 149, 142, 149, 143)","categories":[{"measurements":[{"groupId":"OG000","value":"4.0"},{"groupId":"OG001","value":"2.0"},{"groupId":"OG002","value":"0.7"},{"groupId":"OG003","value":"2.0"},{"groupId":"OG004","value":"4.9"}]}]},{"title":"Week 2 (n=154, 154, 147, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5"},{"groupId":"OG001","value":"8.4"},{"groupId":"OG002","value":"7.5"},{"groupId":"OG003","value":"3.9"},{"groupId":"OG004","value":"12.1"}]}]},{"title":"Week 4 (n=154, 154, 148, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"10.4"},{"groupId":"OG001","value":"13.6"},{"groupId":"OG002","value":"11.5"},{"groupId":"OG003","value":"13.0"},{"groupId":"OG004","value":"17.4"}]}]},{"title":"Week 6 (n=154, 154, 148, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"16.2"},{"groupId":"OG001","value":"14.9"},{"groupId":"OG002","value":"14.9"},{"groupId":"OG003","value":"16.9"},{"groupId":"OG004","value":"20.8"}]}]},{"title":"Week 8 (n=154, 154, 148, 154, 149)","categories":[{"measurements":[{"groupId":"OG000","value":"22.1"},{"groupId":"OG001","value":"20.1"},{"groupId":"OG002","value":"19.6"},{"groupId":"OG003","value":"20.1"},{"groupId":"OG004","value":"28.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)","description":"The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1, 2, 4, 6 and 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"147"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"148"}]}],"classes":[{"title":"Week 1 (n=151, 148, 141, 149, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.055"},{"groupId":"OG001","value":"-0.37","spread":"0.055"},{"groupId":"OG002","value":"-0.39","spread":"0.056"},{"groupId":"OG003","value":"-0.42","spread":"0.054"},{"groupId":"OG004","value":"-0.54","spread":"0.057"}]}]},{"title":"Week 2 (n=147, 145, 142, 147, 130)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"0.066"},{"groupId":"OG001","value":"-0.74","spread":"0.066"},{"groupId":"OG002","value":"-0.80","spread":"0.067"},{"groupId":"OG003","value":"-0.75","spread":"0.065"},{"groupId":"OG004","value":"-0.97","spread":"0.069"}]}]},{"title":"Week 4 (n=140, 135, 132, 134, 115)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.076"},{"groupId":"OG001","value":"-1.12","spread":"0.077"},{"groupId":"OG002","value":"-1.02","spread":"0.077"},{"groupId":"OG003","value":"-1.11","spread":"0.076"},{"groupId":"OG004","value":"-1.28","spread":"0.082"}]}]},{"title":"Week 6 (n=127, 123, 121, 120, 112)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"0.083"},{"groupId":"OG001","value":"-1.32","spread":"0.084"},{"groupId":"OG002","value":"-1.31","spread":"0.084"},{"groupId":"OG003","value":"-1.35","spread":"0.084"},{"groupId":"OG004","value":"-1.55","spread":"0.088"}]}]},{"title":"Week 8 (n=120, 118, 114, 111, 106)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","spread":"0.095"},{"groupId":"OG001","value":"-1.50","spread":"0.096"},{"groupId":"OG002","value":"-1.38","spread":"0.097"},{"groupId":"OG003","value":"-1.44","spread":"0.097"},{"groupId":"OG004","value":"-1.77","spread":"0.101"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed","description":"The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.","populationDescription":"Full analysis set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; \"n\" indicates the number of patients included in the analysis at each time point.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"Baseline to Weeks 1, 4 and 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"148"}]}],"classes":[{"title":"Week 1 (n=150, 149, 141, 149, 141)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"0.226"},{"groupId":"OG001","value":"-0.83","spread":"0.226"},{"groupId":"OG002","value":"-0.88","spread":"0.231"},{"groupId":"OG003","value":"-1.25","spread":"0.225"},{"groupId":"OG004","value":"-1.19","spread":"0.235"}]}]},{"title":"Week 4 (n=141, 142, 139, 141, 126)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.268"},{"groupId":"OG001","value":"-1.83","spread":"0.268"},{"groupId":"OG002","value":"-1.70","spread":"0.271"},{"groupId":"OG003","value":"-1.61","spread":"0.268"},{"groupId":"OG004","value":"-2.62","spread":"0.283"}]}]},{"title":"Week 8 (n=123, 120, 119, 111, 108)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.21","spread":"0.300"},{"groupId":"OG001","value":"-1.82","spread":"0.303"},{"groupId":"OG002","value":"-1.96","spread":"0.305"},{"groupId":"OG003","value":"-1.94","spread":"0.310"},{"groupId":"OG004","value":"-2.77","spread":"0.320"}]}]}]},{"type":"SECONDARY","title":"Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire","description":"Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline and Week 8","groups":[{"id":"OG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks."},{"id":"OG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week."},{"id":"OG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week."},{"id":"OG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"148"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"149"}]}],"classes":[{"title":"Baseline: Any resource use","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"38"}]}]},{"title":"Baseline: Any hospitalization-related services","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Baseline: Hospitalization related to anxiety","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Baseline: Any sick leave","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"12"}]}]},{"title":"Baseline: Sick leave related to anxiety","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}]}]},{"title":"Week 8: Any resource use","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"}]}]},{"title":"Week 8: Any hospitalization-related service","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"Week 8: Hospitalization related to anxiety","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Week 8: Any sick leave","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"11"}]}]},{"title":"Week 8: Sick leave related to anxiety","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From the first dose of double-blind study medication through 30 days after permanent discontinuation of double-blind study medication.","description":"At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Placebo-matching capsules, orally, once daily for up to 9 weeks.","seriousNumAffected":0,"seriousNumAtRisk":155,"otherNumAffected":85,"otherNumAtRisk":155},{"id":"EG001","title":"Vortioxetine 2.5 mg","description":"Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.","seriousNumAffected":1,"seriousNumAtRisk":156,"otherNumAffected":100,"otherNumAtRisk":156},{"id":"EG002","title":"Vortioxetine 5 mg","description":"Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsule, orally, once daily, for 1 week.","seriousNumAffected":0,"seriousNumAtRisk":155,"otherNumAffected":104,"otherNumAtRisk":155},{"id":"EG003","title":"Vortioxetine 10 mg","description":"Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.","seriousNumAffected":1,"seriousNumAtRisk":156,"otherNumAffected":111,"otherNumAtRisk":156},{"id":"EG004","title":"Duloxetine 60 mg","description":"Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.","seriousNumAffected":3,"seriousNumAtRisk":154,"otherNumAffected":116,"otherNumAtRisk":154}],"seriousEvents":[{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Abdominal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":1,"numAtRisk":156},{"groupId":"EG004","numAffected":0,"numAtRisk":154}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":1,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":0,"numAtRisk":154}]},{"term":"Sexual abuse","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]}],"otherEvents":[{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":1,"numAtRisk":155},{"groupId":"EG003","numAffected":4,"numAtRisk":156},{"groupId":"EG004","numAffected":4,"numAtRisk":154}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":155},{"groupId":"EG001","numAffected":26,"numAtRisk":156},{"groupId":"EG002","numAffected":45,"numAtRisk":155},{"groupId":"EG003","numAffected":53,"numAtRisk":156},{"groupId":"EG004","numAffected":57,"numAtRisk":154}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":155},{"groupId":"EG001","numAffected":14,"numAtRisk":156},{"groupId":"EG002","numAffected":17,"numAtRisk":155},{"groupId":"EG003","numAffected":21,"numAtRisk":156},{"groupId":"EG004","numAffected":25,"numAtRisk":154}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":155},{"groupId":"EG001","numAffected":9,"numAtRisk":156},{"groupId":"EG002","numAffected":11,"numAtRisk":155},{"groupId":"EG003","numAffected":20,"numAtRisk":156},{"groupId":"EG004","numAffected":6,"numAtRisk":154}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":155},{"groupId":"EG001","numAffected":10,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":12,"numAtRisk":156},{"groupId":"EG004","numAffected":8,"numAtRisk":154}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":11,"numAtRisk":155},{"groupId":"EG003","numAffected":11,"numAtRisk":156},{"groupId":"EG004","numAffected":3,"numAtRisk":154}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":155},{"groupId":"EG001","numAffected":5,"numAtRisk":156},{"groupId":"EG002","numAffected":5,"numAtRisk":155},{"groupId":"EG003","numAffected":9,"numAtRisk":156},{"groupId":"EG004","numAffected":10,"numAtRisk":154}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":155},{"groupId":"EG001","numAffected":5,"numAtRisk":156},{"groupId":"EG002","numAffected":2,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Stomach discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":155},{"groupId":"EG001","numAffected":1,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":1,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":155},{"groupId":"EG001","numAffected":4,"numAtRisk":156},{"groupId":"EG002","numAffected":3,"numAtRisk":155},{"groupId":"EG003","numAffected":4,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":155},{"groupId":"EG001","numAffected":6,"numAtRisk":156},{"groupId":"EG002","numAffected":8,"numAtRisk":155},{"groupId":"EG003","numAffected":9,"numAtRisk":156},{"groupId":"EG004","numAffected":15,"numAtRisk":154}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":155},{"groupId":"EG001","numAffected":6,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":4,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":155},{"groupId":"EG001","numAffected":3,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Feeling jittery","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":1,"numAtRisk":155},{"groupId":"EG003","numAffected":4,"numAtRisk":156},{"groupId":"EG004","numAffected":4,"numAtRisk":154}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":155},{"groupId":"EG001","numAffected":14,"numAtRisk":156},{"groupId":"EG002","numAffected":7,"numAtRisk":155},{"groupId":"EG003","numAffected":12,"numAtRisk":156},{"groupId":"EG004","numAffected":3,"numAtRisk":154}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":155},{"groupId":"EG001","numAffected":12,"numAtRisk":156},{"groupId":"EG002","numAffected":11,"numAtRisk":155},{"groupId":"EG003","numAffected":12,"numAtRisk":156},{"groupId":"EG004","numAffected":8,"numAtRisk":154}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":155},{"groupId":"EG001","numAffected":1,"numAtRisk":156},{"groupId":"EG002","numAffected":6,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":155},{"groupId":"EG001","numAffected":5,"numAtRisk":156},{"groupId":"EG002","numAffected":6,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":155},{"groupId":"EG001","numAffected":1,"numAtRisk":156},{"groupId":"EG002","numAffected":0,"numAtRisk":155},{"groupId":"EG003","numAffected":0,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":155},{"groupId":"EG001","numAffected":3,"numAtRisk":156},{"groupId":"EG002","numAffected":1,"numAtRisk":155},{"groupId":"EG003","numAffected":1,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":1,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":5,"numAtRisk":155},{"groupId":"EG003","numAffected":5,"numAtRisk":156},{"groupId":"EG004","numAffected":11,"numAtRisk":154}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":0,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":1,"numAtRisk":154}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":155},{"groupId":"EG001","numAffected":18,"numAtRisk":156},{"groupId":"EG002","numAffected":20,"numAtRisk":155},{"groupId":"EG003","numAffected":25,"numAtRisk":156},{"groupId":"EG004","numAffected":26,"numAtRisk":154}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":155},{"groupId":"EG001","numAffected":7,"numAtRisk":156},{"groupId":"EG002","numAffected":13,"numAtRisk":155},{"groupId":"EG003","numAffected":8,"numAtRisk":156},{"groupId":"EG004","numAffected":18,"numAtRisk":154}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":155},{"groupId":"EG001","numAffected":13,"numAtRisk":156},{"groupId":"EG002","numAffected":9,"numAtRisk":155},{"groupId":"EG003","numAffected":14,"numAtRisk":156},{"groupId":"EG004","numAffected":17,"numAtRisk":154}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":155},{"groupId":"EG001","numAffected":4,"numAtRisk":156},{"groupId":"EG002","numAffected":4,"numAtRisk":155},{"groupId":"EG003","numAffected":5,"numAtRisk":156},{"groupId":"EG004","numAffected":2,"numAtRisk":154}]},{"term":"Libido decreased","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":155},{"groupId":"EG001","numAffected":3,"numAtRisk":156},{"groupId":"EG002","numAffected":7,"numAtRisk":155},{"groupId":"EG003","numAffected":3,"numAtRisk":156},{"groupId":"EG004","numAffected":7,"numAtRisk":154}]},{"term":"Anorgasmia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":1,"numAtRisk":156},{"groupId":"EG002","numAffected":1,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":6,"numAtRisk":154}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":155},{"groupId":"EG001","numAffected":6,"numAtRisk":156},{"groupId":"EG002","numAffected":6,"numAtRisk":155},{"groupId":"EG003","numAffected":5,"numAtRisk":156},{"groupId":"EG004","numAffected":6,"numAtRisk":154}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":3,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":5,"numAtRisk":154}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":155},{"groupId":"EG001","numAffected":3,"numAtRisk":156},{"groupId":"EG002","numAffected":5,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":4,"numAtRisk":154}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":1,"numAtRisk":155},{"groupId":"EG003","numAffected":5,"numAtRisk":156},{"groupId":"EG004","numAffected":0,"numAtRisk":154}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":155},{"groupId":"EG001","numAffected":2,"numAtRisk":156},{"groupId":"EG002","numAffected":3,"numAtRisk":155},{"groupId":"EG003","numAffected":2,"numAtRisk":156},{"groupId":"EG004","numAffected":8,"numAtRisk":154}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."},"pointOfContact":{"title":"Medical Director, Clinical Science","organization":"Takeda","email":"clinicaltrialregistry@tpna.com","phone":"800-778-2860"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D000098647","term":"Generalized Anxiety Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001008","term":"Anxiety Disorders"}],"ancestors":[{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000078784","term":"Vortioxetine"},{"id":"D000068736","term":"Duloxetine Hydrochloride"}],"ancestors":[{"id":"D010879","term":"Piperazines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}